DVAX · As filed with the SEC
Dynavax Technologies income statement, by fiscal year
The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 | FY2020 Year ended Dec 31, 2020 | FY2019 Year ended Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Revenues: | ||||||
| Total revenues | 277,246 | 232,284 | 722,683 | 439,442 | 46,551 | 35,219 |
| Product revenue | 268,430 | 213,295 | 713,645 | 437,099 | 39,307 | 34,644 |
| Other revenue | 8,816 | 18,989 | 9,038 | 2,343 | 7,244 | 575 |
| Operating expenses: | ||||||
| Cost of sales - product | 49,445 | 50,167 | 262,153 | 173,572 | 11,410 | 10,172 |
| Cost of sales - amortization of intangible assets | — | — | 0 | 0 | 2,500 | 9,217 |
| Research and development | 61,550 | 54,886 | 46,600 | 32,228 | 28,607 | 62,331 |
| Selling, general and administrative | 170,373 | 152,946 | 131,408 | 100,156 | 79,256 | 74,986 |
| Gain on sale of assets (Note 8) | 0 | (1,000) | (1,000) | (1,000) | (6,851) | 0 |
| Bad debt expense (Note 9) | 0 | 12,313 | — | — | — | — |
| Restructuring | — | — | — | 0 | 0 | 13,356 |
| Total operating expenses | 281,368 | 269,312 | 439,161 | 304,956 | 114,922 | 170,062 |
| (Loss) income from operations | (4,122) | (37,028) | 283,522 | 134,486 | (68,371) | (134,843) |
| Other (expense) income: | ||||||
| Interest income | 36,464 | 31,993 | 7,912 | 140 | 1,260 | 3,370 |
| Interest expense | — | (6,757,000) | (6,732,000) | (11,176,000) | (19,062,000) | (16,977,000) |
| Interest expense | (6,794) | — | — | — | — | — |
| Sublease income | 5,014 | 7,577 | 7,685 | 7,735 | 7,706 | 2,619 |
| Loss on debt extinguishment (Note 11) | — | 0 | 0 | (5,232,000) | 0 | 0 |
| Change in fair value of warrant liability (Note 14) | 0 | 0 | 1,801 | (49,354) | 4,124 | (7,500) |
| Other | 293 | (152) | 111 | 922 | (897) | 731 |
| Net income (loss) before income taxes | 30,855 | (4,367) | 294,299 | 77,521 | (75,240) | (152,600) |
| Provision for income taxes | (3,546) | (2,022) | (1,143) | (808) | 0 | 0 |
| Net income (loss) | 27,309 | (6,389) | 293,156 | 76,713 | (75,240) | (152,600) |
| Undistributed earnings allocated to participating securities | 0 | 0 | (283) | (4,569) | 0 | 0 |
| Preferred stock deemed dividend | — | — | — | 0 | 0 | (3,267,000) |
| Net (loss) income allocable to common stockholders, basic (in USD per share) | 27,309 | (6,389) | 292,873 | 72,144 | (75,240) | (155,867) |
| Net income (loss) per share allocable to common stockholders | ||||||
| Basic (in USD per share) | 0.21 | (0.05) | 2.32 | 0.62 | (0.75) | (2.16) |
| Diluted (in USD per share) | 0.20 | (0.05) | 1.97 | 0.57 | (0.78) | (2.16) |
| Weighted-average shares used in computing net income (loss) per share allocable to common stockholders: | ||||||
| Basic (in shares) | 130,047 | 128,733 | 126,398 | 116,264 | 100,753 | 72,024 |
| Diluted (in shares) | 133,344 | 128,733 | 150,797 | 133,006 | 101,504 | 72,024 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.